Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.

Basit Öğe Kaydı
dc.contributor.authorIcli, F.
dc.contributor.authorAltundag, K.
dc.contributor.authorCoskun, U.
dc.contributor.authorPaydas, S.
dc.contributor.authorBasaran, G.
dc.contributor.authorSaip, P.
dc.contributor.authorDogu, G. G.
dc.contributor.authorEralp, Y.
dc.contributor.authorUslu, R.
dc.contributor.authorSevinc, A.
dc.contributor.authorOnur, H.
dc.contributor.authorMandel, N. M.
dc.contributor.authorSezgin, C.
dc.contributor.authorAltinbas, M.
dc.contributor.authorGuler, N.
dc.contributor.authorIsikdogan, A.
dc.contributor.authorGokmen, E.
dc.contributor.authorUygun, K.
dc.contributor.authorUstuner, Z.
dc.contributor.authorYaren, A.
dc.date.accessioned2019-10-27T21:24:15Z
dc.date.available2019-10-27T21:24:15Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.identifier.doi10.1200/jco.2011.29.15_suppl.629
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/jco.2011.29.15_suppl.629
dc.identifier.urihttps://hdl.handle.net/11454/44457
dc.identifier.volume29en_US
dc.identifier.wosWOS:000208880300132en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleNine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu